Adult Preventable Vaccines Decade Long Trends, Analysis and Forecast 2025-2033
Adult Preventable Vaccines by Type (Inactivated Vaccines, Subunit Vaccines, Mrna Vaccines, Viral Vector Vaccines, Peptide Vaccines, World Adult Preventable Vaccines Production ), by Application (Prevent Influenza, Prevent Pneumococcal Infection, Prevent Hepatitis B, Prevent Herpes Zoster, Prevent Human Papillomavirus (Hpv), Other), by North America (United States, Canada, Mexico), by South America (Brazil, Argentina, Rest of South America), by Europe (United Kingdom, Germany, France, Italy, Spain, Russia, Benelux, Nordics, Rest of Europe), by Middle East & Africa (Turkey, Israel, GCC, North Africa, South Africa, Rest of Middle East & Africa), by Asia Pacific (China, India, Japan, South Korea, ASEAN, Oceania, Rest of Asia Pacific) Forecast 2026-2034
Base Year: 2025
116 Pages
Adult Preventable Vaccines Decade Long Trends, Analysis and Forecast 2025-2033
Adult Preventable Vaccines Decade Long Trends, Analysis and Forecast 2025-2033
About Market Research Forecast
MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.
Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.
The global market for Adult Preventable Vaccines is poised for significant expansion, projected to reach approximately USD 29,810 million by 2025. This robust growth is fueled by an increasing awareness of vaccine-preventable diseases among adult populations, coupled with advancements in vaccine technology. Key market drivers include the rising incidence of chronic and infectious diseases, the growing demand for prophylactic healthcare measures, and supportive government initiatives aimed at increasing adult vaccination rates. Furthermore, the introduction of novel vaccine platforms, such as mRNA and viral vector vaccines, is revolutionizing the landscape, offering enhanced efficacy and faster development cycles. The market is segmented by vaccine type, with Inactivated Vaccines and Subunit Vaccines currently holding substantial shares due to their established safety profiles and widespread use. However, mRNA and Viral Vector Vaccines are exhibiting rapid growth potential, driven by their adaptability and effectiveness demonstrated during recent global health crises. Applications like preventing influenza, pneumococcal infections, hepatitis B, and HPV are major revenue generators, reflecting the ongoing public health focus on these prevalent conditions.
Adult Preventable Vaccines Market Size (In Billion)
50.0B
40.0B
30.0B
20.0B
10.0B
0
29.81 B
2025
31.75 B
2026
33.82 B
2027
36.02 B
2028
38.35 B
2029
40.82 B
2030
43.43 B
2031
The competitive environment is dynamic, featuring major pharmaceutical giants like Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc (GSK), and Sanofi Pasteur, alongside innovative players such as Moderna, Inc. and Novavax, Inc. These companies are actively investing in research and development to broaden their vaccine portfolios and address unmet medical needs. Geographically, North America and Europe currently dominate the market, owing to advanced healthcare infrastructure, high disposable incomes, and robust vaccination programs. However, the Asia Pacific region is emerging as a key growth engine, propelled by a large, aging population, increasing healthcare expenditure, and a growing presence of domestic vaccine manufacturers like the Serum Institute of India and Sinovac Biotech. Despite the positive outlook, challenges such as vaccine hesitancy, reimbursement policies, and the high cost of novel vaccines can pose restraints. Nevertheless, the overarching trend towards proactive healthcare and the continuous innovation in vaccine science are expected to sustain a healthy Compound Annual Growth Rate (CAGR) of approximately 6.5% through the forecast period of 2025-2033.
Adult Preventable Vaccines Company Market Share
Loading chart...
This comprehensive report provides an in-depth analysis of the global Adult Preventable Vaccines market, offering critical insights and forecasts for stakeholders. Spanning a study period from 2019 to 2033, with a base year of 2025 and an estimated year of 2025, the report leverages historical data from 2019-2024 and projects future trends through the forecast period of 2025-2033. The analysis focuses on the production and application of vaccines designed to prevent a range of infectious diseases in adults, with an emphasis on market dynamics, driving forces, challenges, regional dominance, growth catalysts, and the competitive landscape. The report will utilize production volume figures in the million unit range for its quantitative analysis.
Adult Preventable Vaccines Trends
XXX, the global market for adult preventable vaccines is poised for significant expansion, driven by a confluence of factors that underscore the increasing recognition of adult immunization as a critical public health imperative. Throughout the historical period (2019-2024), the market witnessed steady growth, fueled by rising awareness campaigns and the introduction of novel vaccine formulations. The base year of 2025 represents a pivotal point, from which the market is projected to accelerate its trajectory through 2033. Key trends indicate a substantial increase in the production and uptake of vaccines targeting common and serious adult infections.
The increasing prevalence of chronic diseases, coupled with the aging global population, amplifies the susceptibility of adults to preventable infections, thereby creating a sustained demand for robust vaccination programs. Furthermore, the evolving landscape of infectious diseases, including the ongoing impact of pandemics and the emergence of new pathogens, has underscored the importance of broad-spectrum adult immunization strategies. The market is characterized by a dynamic interplay between established vaccine technologies and the rapid advancement of novel platforms, particularly mRNA and viral vector vaccines, which have demonstrated remarkable efficacy and adaptability. This innovation is not only expanding the portfolio of available vaccines but also enhancing their accessibility and effectiveness. The focus on preventative healthcare is shifting from childhood immunizations to a more holistic approach that encompasses the entire lifespan, recognizing the continued vulnerability of adults to various preventable diseases. This paradigm shift is expected to translate into substantial market growth, with production volumes projected to reach hundreds of millions of units annually by the end of the forecast period. The market's growth will be further influenced by evolving regulatory frameworks, reimbursement policies, and the strategic investments made by leading pharmaceutical companies in research and development. The economic benefits of adult vaccination, in terms of reduced healthcare costs and improved productivity, are becoming increasingly evident, further bolstering the market's expansion.
Driving Forces: What's Propelling the Adult Preventable Vaccines
Several potent forces are collaboratively driving the substantial growth witnessed and anticipated in the adult preventable vaccines market. Foremost among these is the undeniable demographic shift towards an aging global population. As individuals live longer, their susceptibility to various infectious diseases, often exacerbated by weakened immune systems or underlying chronic conditions, increases significantly. This demographic reality directly translates into a larger at-risk adult population requiring proactive immunization. Concurrently, there is a heightened and evolving public health awareness regarding the benefits of adult vaccination. Governments and healthcare organizations worldwide are increasingly advocating for comprehensive adult immunization schedules, recognizing that preventing disease in adults not only safeguards individual well-being but also reduces the burden on healthcare systems and boosts economic productivity. The economic argument for preventative healthcare is becoming more persuasive; the cost of vaccinating an adult is demonstrably lower than the cost of treating a severe infection and its potential complications. This has led to greater investment in public health initiatives and improved reimbursement policies for adult vaccines. Furthermore, the persistent threat of emerging infectious diseases, exemplified by recent global pandemics, has served as a stark reminder of the critical role vaccines play in public health security. This heightened awareness compels individuals and policymakers to prioritize and invest in a robust pipeline of adult vaccines. The continuous innovation in vaccine technology, particularly the rapid development and successful deployment of mRNA vaccines, has broadened the scope of preventable diseases and improved vaccine efficacy, further fueling market demand.
Challenges and Restraints in Adult Preventable Vaccines
Despite the promising growth trajectory, the adult preventable vaccines market faces a complex interplay of challenges and restraints that can potentially impede its full realization. A significant hurdle is the persistent issue of vaccine hesitancy and misinformation. While awareness of vaccine benefits is growing, a segment of the adult population remains skeptical, influenced by anecdotal evidence, unfounded fears, or distrust in medical institutions. This can lead to lower uptake rates, even for highly effective vaccines. The cost of vaccines and their accessibility, particularly in low- and middle-income countries, also presents a considerable challenge. While major players are investing in production, ensuring equitable access to a wide range of adult vaccines globally remains a complex logistical and financial undertaking. The development of new vaccines is a lengthy and expensive process, subject to rigorous regulatory scrutiny. Delays in clinical trials, manufacturing complexities, and the sheer cost of research and development can slow down the introduction of new vaccines to the market, thereby limiting the options available for disease prevention. Furthermore, market access and reimbursement policies can vary significantly across different regions, creating a fragmented landscape for vaccine manufacturers and impacting the widespread adoption of adult immunization programs. The complex supply chains and cold chain requirements for certain vaccines can also pose logistical challenges, particularly in regions with underdeveloped infrastructure, potentially leading to vaccine wastage or reduced efficacy.
Key Region or Country & Segment to Dominate the Market
The global adult preventable vaccines market is characterized by dynamic regional and segmental dominance, with specific areas and vaccine types demonstrating particularly strong growth potential.
Dominant Segments by Type:
Inactivated Vaccines: These vaccines, such as those for influenza and certain types of pneumococcal infections, have a long-established track record and continue to be a cornerstone of adult immunization. Their proven safety and efficacy, coupled with widespread availability and physician familiarity, ensure their continued dominance, especially in preventing influenza. Their production volumes are expected to remain in the tens to hundreds of millions of units annually.
Subunit Vaccines: This category, which includes vaccines for Hepatitis B and increasingly for Human Papillomavirus (HPV), is experiencing robust growth. The targeted nature of subunit vaccines, using specific antigens, often leads to a favorable safety profile and high efficacy. The increasing focus on preventing HPV-related cancers and the ongoing need for Hepatitis B protection contribute significantly to the market share of this segment.
mRNA Vaccines: While newer to the market in the context of adult preventable diseases beyond COVID-19, mRNA vaccines are rapidly emerging as a dominant force due to their adaptability, speed of development, and potential for broad applications. Their ability to elicit strong immune responses positions them for significant future growth, particularly as research expands into other adult infectious diseases.
Viral Vector Vaccines: Similar to mRNA, viral vector vaccines have gained prominence with recent pandemic responses and hold substantial promise for future applications in adult immunization. Their established efficacy in delivering antigens makes them a key player in the growing market.
Dominant Segments by Application:
Prevent Influenza: Influenza remains a leading cause of morbidity and mortality in adults, making influenza vaccines a perennial and consistently high-demand product. The annual need for vaccination due to viral evolution ensures a stable and substantial market. Production for influenza vaccines alone can reach hundreds of millions of units globally.
Prevent Pneumococcal Infection: With the increasing incidence of pneumococcal diseases, particularly in older adults and immunocompromised individuals, pneumococcal vaccines are a critical component of adult vaccination strategies. The introduction of newer, broader-spectrum pneumococcal vaccines further fuels this segment's growth. Production for pneumococcal vaccines is also expected to be in the tens to hundreds of millions of units.
Prevent Human Papillomavirus (HPV): The growing recognition of HPV's role in various cancers, including cervical, anal, and oropharyngeal cancers, has led to a significant expansion in HPV vaccination recommendations for adults. This segment is poised for substantial growth as awareness and access improve.
Prevent Herpes Zoster (Shingles): As the population ages, the incidence of shingles and its complications increases, driving demand for herpes zoster vaccines. This segment is expected to see consistent growth as more adults become eligible and aware of the benefits.
Key Dominant Regions/Countries:
North America (United States and Canada): This region consistently leads the global market due to high disposable incomes, robust healthcare infrastructure, well-established vaccination programs, and a strong emphasis on preventative healthcare. The presence of major vaccine manufacturers and extensive research and development activities further solidify its dominance. The market here will see a significant volume of millions of units for all major vaccine types.
Europe: With a well-developed healthcare system and strong government initiatives promoting adult immunization, Europe represents another dominant region. Countries like Germany, France, the UK, and the Nordic nations have high vaccination rates and a growing demand for a comprehensive range of adult vaccines.
Asia-Pacific (China, India, Japan, South Korea): This region is witnessing the fastest growth rate. Countries like India and China, with their massive populations, represent significant untapped potential and are experiencing a surge in domestic production and increasing adoption of adult vaccination programs. Japan and South Korea, with their aging populations and advanced healthcare systems, also contribute significantly to market volume, with millions of units produced and utilized. The growing middle class and increased health consciousness are key drivers in this region.
The interplay of these dominant segments, driven by both established needs and emerging threats, will shape the overall market landscape, with a projected combined production volume in the hundreds of millions of units across key applications and vaccine types.
Growth Catalysts in Adult Preventable Vaccines Industry
The adult preventable vaccines industry is experiencing significant growth catalysts that are poised to shape its future. A primary catalyst is the increasing investment in research and development by leading pharmaceutical companies. This focus on innovation is leading to the development of novel vaccines for a wider range of adult diseases and the improvement of existing vaccine technologies. Furthermore, government initiatives and public health campaigns promoting adult vaccination are playing a crucial role in raising awareness and encouraging uptake. The growing burden of chronic diseases and the aging global population are also significant drivers, as these demographic shifts increase the susceptibility of adults to vaccine-preventable infections. The successful development and deployment of mRNA and viral vector vaccine technologies have also opened new avenues for rapid vaccine development and broader application, acting as a powerful catalyst for market expansion.
Leading Players in the Adult Preventable Vaccines
Pfizer Inc.
Merck & Co., Inc.
GlaxoSmithKline plc (GSK)
Sanofi Pasteur
Moderna, Inc.
Serum Institute of India Pvt.
Bharat Biotech International
CSL Limited (Seqirus)
Emergent BioSolutions Inc.
Daiichi Sankyo Company
Novavax, Inc.
Sinovac Biotech
Sinopharm Group Co.,
Johnson & Johnson (Janssen)
AstraZeneca plc
Significant Developments in Adult Preventable Vaccines Sector
2023: Approval and rollout of new-generation pneumococcal vaccines offering broader serotype coverage for adults.
2024: Increased focus on research and clinical trials for mRNA-based vaccines targeting respiratory syncytial virus (RSV) in older adults.
2025 (Estimated): Anticipated regulatory submissions for novel vaccines against emerging infectious diseases, leveraging advanced platform technologies.
2026: Potential for expanded indications for existing HPV vaccines to include a wider age range of adults.
2028: Expected advancements in combination vaccines for adults, offering protection against multiple diseases with a single administration.
2030: Significant market penetration of next-generation influenza vaccines with improved efficacy and longer-lasting protection.
2032: Emerging research and early-stage trials for vaccines targeting other significant adult health concerns, such as certain autoimmune diseases.
2033: Continued evolution and refinement of viral vector and mRNA platforms for enhanced safety and immunogenicity in adult populations.
This report offers a comprehensive coverage of the adult preventable vaccines market, providing a holistic view of its complexities and opportunities. Beyond market size and forecasts, it delves into the key industry developments, including the impact of technological advancements and the evolving regulatory landscape. The report meticulously examines the driving forces and challenges that shape market dynamics, offering a balanced perspective on growth prospects. A significant focus is placed on leading players and their strategic initiatives, providing insights into the competitive landscape and potential for market consolidation or expansion. The analysis extends to a granular breakdown of market segmentation by vaccine type (Inactivated, Subunit, mRNA, Viral Vector, Peptide) and application (Influenza, Pneumococcal Infection, Hepatitis B, Herpes Zoster, HPV, and Others), allowing for a nuanced understanding of specific product performances. Furthermore, the report identifies key regions and countries poised for market dominance, highlighting the factors contributing to their leadership. This comprehensive approach ensures that stakeholders are equipped with the detailed information necessary to make informed strategic decisions within this vital sector of global public health.
Adult Preventable Vaccines Segmentation
1. Type
1.1. Inactivated Vaccines
1.2. Subunit Vaccines
1.3. Mrna Vaccines
1.4. Viral Vector Vaccines
1.5. Peptide Vaccines
1.6. World Adult Preventable Vaccines Production
2. Application
2.1. Prevent Influenza
2.2. Prevent Pneumococcal Infection
2.3. Prevent Hepatitis B
2.4. Prevent Herpes Zoster
2.5. Prevent Human Papillomavirus (Hpv)
2.6. Other
Adult Preventable Vaccines Segmentation By Geography
1. North America
1.1. United States
1.2. Canada
1.3. Mexico
2. South America
2.1. Brazil
2.2. Argentina
2.3. Rest of South America
3. Europe
3.1. United Kingdom
3.2. Germany
3.3. France
3.4. Italy
3.5. Spain
3.6. Russia
3.7. Benelux
3.8. Nordics
3.9. Rest of Europe
4. Middle East & Africa
4.1. Turkey
4.2. Israel
4.3. GCC
4.4. North Africa
4.5. South Africa
4.6. Rest of Middle East & Africa
5. Asia Pacific
5.1. China
5.2. India
5.3. Japan
5.4. South Korea
5.5. ASEAN
5.6. Oceania
5.7. Rest of Asia Pacific
Adult Preventable Vaccines Regional Market Share
Loading chart...
Geographic Coverage of Adult Preventable Vaccines
Higher Coverage
Lower Coverage
No Coverage
Adult Preventable Vaccines REPORT HIGHLIGHTS
Aspects
Details
Study Period
2020-2034
Base Year
2025
Estimated Year
2026
Forecast Period
2026-2034
Historical Period
2020-2025
Growth Rate
CAGR of XX% from 2020-2034
Segmentation
By Type
Inactivated Vaccines
Subunit Vaccines
Mrna Vaccines
Viral Vector Vaccines
Peptide Vaccines
World Adult Preventable Vaccines Production
By Application
Prevent Influenza
Prevent Pneumococcal Infection
Prevent Hepatitis B
Prevent Herpes Zoster
Prevent Human Papillomavirus (Hpv)
Other
By Geography
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Rest of South America
Europe
United Kingdom
Germany
France
Italy
Spain
Russia
Benelux
Nordics
Rest of Europe
Middle East & Africa
Turkey
Israel
GCC
North Africa
South Africa
Rest of Middle East & Africa
Asia Pacific
China
India
Japan
South Korea
ASEAN
Oceania
Rest of Asia Pacific
Table of Contents
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
2.1. Introduction
3. Market Dynamics
3.1. Introduction
3.2. Market Drivers
3.3. Market Restrains
3.4. Market Trends
4. Market Factor Analysis
4.1. Porters Five Forces
4.2. Supply/Value Chain
4.3. PESTEL analysis
4.4. Market Entropy
4.5. Patent/Trademark Analysis
5. Global Adult Preventable Vaccines Analysis, Insights and Forecast, 2020-2032
5.1. Market Analysis, Insights and Forecast - by Type
5.1.1. Inactivated Vaccines
5.1.2. Subunit Vaccines
5.1.3. Mrna Vaccines
5.1.4. Viral Vector Vaccines
5.1.5. Peptide Vaccines
5.1.6. World Adult Preventable Vaccines Production
5.2. Market Analysis, Insights and Forecast - by Application
5.2.1. Prevent Influenza
5.2.2. Prevent Pneumococcal Infection
5.2.3. Prevent Hepatitis B
5.2.4. Prevent Herpes Zoster
5.2.5. Prevent Human Papillomavirus (Hpv)
5.2.6. Other
5.3. Market Analysis, Insights and Forecast - by Region
5.3.1. North America
5.3.2. South America
5.3.3. Europe
5.3.4. Middle East & Africa
5.3.5. Asia Pacific
6. North America Adult Preventable Vaccines Analysis, Insights and Forecast, 2020-2032
6.1. Market Analysis, Insights and Forecast - by Type
6.1.1. Inactivated Vaccines
6.1.2. Subunit Vaccines
6.1.3. Mrna Vaccines
6.1.4. Viral Vector Vaccines
6.1.5. Peptide Vaccines
6.1.6. World Adult Preventable Vaccines Production
6.2. Market Analysis, Insights and Forecast - by Application
6.2.1. Prevent Influenza
6.2.2. Prevent Pneumococcal Infection
6.2.3. Prevent Hepatitis B
6.2.4. Prevent Herpes Zoster
6.2.5. Prevent Human Papillomavirus (Hpv)
6.2.6. Other
7. South America Adult Preventable Vaccines Analysis, Insights and Forecast, 2020-2032
7.1. Market Analysis, Insights and Forecast - by Type
7.1.1. Inactivated Vaccines
7.1.2. Subunit Vaccines
7.1.3. Mrna Vaccines
7.1.4. Viral Vector Vaccines
7.1.5. Peptide Vaccines
7.1.6. World Adult Preventable Vaccines Production
7.2. Market Analysis, Insights and Forecast - by Application
7.2.1. Prevent Influenza
7.2.2. Prevent Pneumococcal Infection
7.2.3. Prevent Hepatitis B
7.2.4. Prevent Herpes Zoster
7.2.5. Prevent Human Papillomavirus (Hpv)
7.2.6. Other
8. Europe Adult Preventable Vaccines Analysis, Insights and Forecast, 2020-2032
8.1. Market Analysis, Insights and Forecast - by Type
8.1.1. Inactivated Vaccines
8.1.2. Subunit Vaccines
8.1.3. Mrna Vaccines
8.1.4. Viral Vector Vaccines
8.1.5. Peptide Vaccines
8.1.6. World Adult Preventable Vaccines Production
8.2. Market Analysis, Insights and Forecast - by Application
8.2.1. Prevent Influenza
8.2.2. Prevent Pneumococcal Infection
8.2.3. Prevent Hepatitis B
8.2.4. Prevent Herpes Zoster
8.2.5. Prevent Human Papillomavirus (Hpv)
8.2.6. Other
9. Middle East & Africa Adult Preventable Vaccines Analysis, Insights and Forecast, 2020-2032
9.1. Market Analysis, Insights and Forecast - by Type
9.1.1. Inactivated Vaccines
9.1.2. Subunit Vaccines
9.1.3. Mrna Vaccines
9.1.4. Viral Vector Vaccines
9.1.5. Peptide Vaccines
9.1.6. World Adult Preventable Vaccines Production
9.2. Market Analysis, Insights and Forecast - by Application
9.2.1. Prevent Influenza
9.2.2. Prevent Pneumococcal Infection
9.2.3. Prevent Hepatitis B
9.2.4. Prevent Herpes Zoster
9.2.5. Prevent Human Papillomavirus (Hpv)
9.2.6. Other
10. Asia Pacific Adult Preventable Vaccines Analysis, Insights and Forecast, 2020-2032
10.1. Market Analysis, Insights and Forecast - by Type
10.1.1. Inactivated Vaccines
10.1.2. Subunit Vaccines
10.1.3. Mrna Vaccines
10.1.4. Viral Vector Vaccines
10.1.5. Peptide Vaccines
10.1.6. World Adult Preventable Vaccines Production
10.2. Market Analysis, Insights and Forecast - by Application
10.2.1. Prevent Influenza
10.2.2. Prevent Pneumococcal Infection
10.2.3. Prevent Hepatitis B
10.2.4. Prevent Herpes Zoster
10.2.5. Prevent Human Papillomavirus (Hpv)
10.2.6. Other
11. Competitive Analysis
11.1. Global Market Share Analysis 2025
11.2. Company Profiles
11.2.1 Pfizer Inc.
11.2.1.1. Overview
11.2.1.2. Products
11.2.1.3. SWOT Analysis
11.2.1.4. Recent Developments
11.2.1.5. Financials (Based on Availability)
11.2.2 Merck & Co. Inc.
11.2.2.1. Overview
11.2.2.2. Products
11.2.2.3. SWOT Analysis
11.2.2.4. Recent Developments
11.2.2.5. Financials (Based on Availability)
11.2.3 GlaxoSmithKline plc (GSK)
11.2.3.1. Overview
11.2.3.2. Products
11.2.3.3. SWOT Analysis
11.2.3.4. Recent Developments
11.2.3.5. Financials (Based on Availability)
11.2.4 Sanofi Pasteur
11.2.4.1. Overview
11.2.4.2. Products
11.2.4.3. SWOT Analysis
11.2.4.4. Recent Developments
11.2.4.5. Financials (Based on Availability)
11.2.5 Moderna Inc.
11.2.5.1. Overview
11.2.5.2. Products
11.2.5.3. SWOT Analysis
11.2.5.4. Recent Developments
11.2.5.5. Financials (Based on Availability)
11.2.6 Serum Institute of India Pvt.
11.2.6.1. Overview
11.2.6.2. Products
11.2.6.3. SWOT Analysis
11.2.6.4. Recent Developments
11.2.6.5. Financials (Based on Availability)
11.2.7 Bharat Biotech International
11.2.7.1. Overview
11.2.7.2. Products
11.2.7.3. SWOT Analysis
11.2.7.4. Recent Developments
11.2.7.5. Financials (Based on Availability)
11.2.8 CSL Limited (Seqirus)
11.2.8.1. Overview
11.2.8.2. Products
11.2.8.3. SWOT Analysis
11.2.8.4. Recent Developments
11.2.8.5. Financials (Based on Availability)
11.2.9 Emergent BioSolutions Inc.
11.2.9.1. Overview
11.2.9.2. Products
11.2.9.3. SWOT Analysis
11.2.9.4. Recent Developments
11.2.9.5. Financials (Based on Availability)
11.2.10 Daiichi Sankyo Company
11.2.10.1. Overview
11.2.10.2. Products
11.2.10.3. SWOT Analysis
11.2.10.4. Recent Developments
11.2.10.5. Financials (Based on Availability)
11.2.11 Novavax Inc.
11.2.11.1. Overview
11.2.11.2. Products
11.2.11.3. SWOT Analysis
11.2.11.4. Recent Developments
11.2.11.5. Financials (Based on Availability)
11.2.12 Sinovac Biotech
11.2.12.1. Overview
11.2.12.2. Products
11.2.12.3. SWOT Analysis
11.2.12.4. Recent Developments
11.2.12.5. Financials (Based on Availability)
11.2.13 Sinopharm Group Co.
11.2.13.1. Overview
11.2.13.2. Products
11.2.13.3. SWOT Analysis
11.2.13.4. Recent Developments
11.2.13.5. Financials (Based on Availability)
11.2.14 Johnson & Johnson (Janssen)
11.2.14.1. Overview
11.2.14.2. Products
11.2.14.3. SWOT Analysis
11.2.14.4. Recent Developments
11.2.14.5. Financials (Based on Availability)
11.2.15 AstraZeneca plc
11.2.15.1. Overview
11.2.15.2. Products
11.2.15.3. SWOT Analysis
11.2.15.4. Recent Developments
11.2.15.5. Financials (Based on Availability)
List of Figures
Figure 1: Global Adult Preventable Vaccines Revenue Breakdown (million, %) by Region 2025 & 2033
Figure 2: Global Adult Preventable Vaccines Volume Breakdown (K, %) by Region 2025 & 2033
Figure 3: North America Adult Preventable Vaccines Revenue (million), by Type 2025 & 2033
Figure 4: North America Adult Preventable Vaccines Volume (K), by Type 2025 & 2033
Figure 5: North America Adult Preventable Vaccines Revenue Share (%), by Type 2025 & 2033
Figure 6: North America Adult Preventable Vaccines Volume Share (%), by Type 2025 & 2033
Figure 7: North America Adult Preventable Vaccines Revenue (million), by Application 2025 & 2033
Figure 8: North America Adult Preventable Vaccines Volume (K), by Application 2025 & 2033
Figure 9: North America Adult Preventable Vaccines Revenue Share (%), by Application 2025 & 2033
Figure 10: North America Adult Preventable Vaccines Volume Share (%), by Application 2025 & 2033
Figure 11: North America Adult Preventable Vaccines Revenue (million), by Country 2025 & 2033
Figure 12: North America Adult Preventable Vaccines Volume (K), by Country 2025 & 2033
Figure 13: North America Adult Preventable Vaccines Revenue Share (%), by Country 2025 & 2033
Figure 14: North America Adult Preventable Vaccines Volume Share (%), by Country 2025 & 2033
Figure 15: South America Adult Preventable Vaccines Revenue (million), by Type 2025 & 2033
Figure 16: South America Adult Preventable Vaccines Volume (K), by Type 2025 & 2033
Figure 17: South America Adult Preventable Vaccines Revenue Share (%), by Type 2025 & 2033
Figure 18: South America Adult Preventable Vaccines Volume Share (%), by Type 2025 & 2033
Figure 19: South America Adult Preventable Vaccines Revenue (million), by Application 2025 & 2033
Figure 20: South America Adult Preventable Vaccines Volume (K), by Application 2025 & 2033
Figure 21: South America Adult Preventable Vaccines Revenue Share (%), by Application 2025 & 2033
Figure 22: South America Adult Preventable Vaccines Volume Share (%), by Application 2025 & 2033
Figure 23: South America Adult Preventable Vaccines Revenue (million), by Country 2025 & 2033
Figure 24: South America Adult Preventable Vaccines Volume (K), by Country 2025 & 2033
Figure 25: South America Adult Preventable Vaccines Revenue Share (%), by Country 2025 & 2033
Figure 26: South America Adult Preventable Vaccines Volume Share (%), by Country 2025 & 2033
Figure 27: Europe Adult Preventable Vaccines Revenue (million), by Type 2025 & 2033
Figure 28: Europe Adult Preventable Vaccines Volume (K), by Type 2025 & 2033
Figure 29: Europe Adult Preventable Vaccines Revenue Share (%), by Type 2025 & 2033
Figure 30: Europe Adult Preventable Vaccines Volume Share (%), by Type 2025 & 2033
Figure 31: Europe Adult Preventable Vaccines Revenue (million), by Application 2025 & 2033
Figure 32: Europe Adult Preventable Vaccines Volume (K), by Application 2025 & 2033
Figure 33: Europe Adult Preventable Vaccines Revenue Share (%), by Application 2025 & 2033
Figure 34: Europe Adult Preventable Vaccines Volume Share (%), by Application 2025 & 2033
Figure 35: Europe Adult Preventable Vaccines Revenue (million), by Country 2025 & 2033
Figure 36: Europe Adult Preventable Vaccines Volume (K), by Country 2025 & 2033
Figure 37: Europe Adult Preventable Vaccines Revenue Share (%), by Country 2025 & 2033
Figure 38: Europe Adult Preventable Vaccines Volume Share (%), by Country 2025 & 2033
Figure 39: Middle East & Africa Adult Preventable Vaccines Revenue (million), by Type 2025 & 2033
Figure 40: Middle East & Africa Adult Preventable Vaccines Volume (K), by Type 2025 & 2033
Figure 41: Middle East & Africa Adult Preventable Vaccines Revenue Share (%), by Type 2025 & 2033
Figure 42: Middle East & Africa Adult Preventable Vaccines Volume Share (%), by Type 2025 & 2033
Figure 43: Middle East & Africa Adult Preventable Vaccines Revenue (million), by Application 2025 & 2033
Figure 44: Middle East & Africa Adult Preventable Vaccines Volume (K), by Application 2025 & 2033
Figure 45: Middle East & Africa Adult Preventable Vaccines Revenue Share (%), by Application 2025 & 2033
Figure 46: Middle East & Africa Adult Preventable Vaccines Volume Share (%), by Application 2025 & 2033
Figure 47: Middle East & Africa Adult Preventable Vaccines Revenue (million), by Country 2025 & 2033
Figure 48: Middle East & Africa Adult Preventable Vaccines Volume (K), by Country 2025 & 2033
Figure 49: Middle East & Africa Adult Preventable Vaccines Revenue Share (%), by Country 2025 & 2033
Figure 50: Middle East & Africa Adult Preventable Vaccines Volume Share (%), by Country 2025 & 2033
Figure 51: Asia Pacific Adult Preventable Vaccines Revenue (million), by Type 2025 & 2033
Figure 52: Asia Pacific Adult Preventable Vaccines Volume (K), by Type 2025 & 2033
Figure 53: Asia Pacific Adult Preventable Vaccines Revenue Share (%), by Type 2025 & 2033
Figure 54: Asia Pacific Adult Preventable Vaccines Volume Share (%), by Type 2025 & 2033
Figure 55: Asia Pacific Adult Preventable Vaccines Revenue (million), by Application 2025 & 2033
Figure 56: Asia Pacific Adult Preventable Vaccines Volume (K), by Application 2025 & 2033
Figure 57: Asia Pacific Adult Preventable Vaccines Revenue Share (%), by Application 2025 & 2033
Figure 58: Asia Pacific Adult Preventable Vaccines Volume Share (%), by Application 2025 & 2033
Figure 59: Asia Pacific Adult Preventable Vaccines Revenue (million), by Country 2025 & 2033
Figure 60: Asia Pacific Adult Preventable Vaccines Volume (K), by Country 2025 & 2033
Figure 61: Asia Pacific Adult Preventable Vaccines Revenue Share (%), by Country 2025 & 2033
Figure 62: Asia Pacific Adult Preventable Vaccines Volume Share (%), by Country 2025 & 2033
List of Tables
Table 1: Global Adult Preventable Vaccines Revenue million Forecast, by Type 2020 & 2033
Table 2: Global Adult Preventable Vaccines Volume K Forecast, by Type 2020 & 2033
Table 3: Global Adult Preventable Vaccines Revenue million Forecast, by Application 2020 & 2033
Table 4: Global Adult Preventable Vaccines Volume K Forecast, by Application 2020 & 2033
Table 5: Global Adult Preventable Vaccines Revenue million Forecast, by Region 2020 & 2033
Table 6: Global Adult Preventable Vaccines Volume K Forecast, by Region 2020 & 2033
Table 7: Global Adult Preventable Vaccines Revenue million Forecast, by Type 2020 & 2033
Table 8: Global Adult Preventable Vaccines Volume K Forecast, by Type 2020 & 2033
Table 9: Global Adult Preventable Vaccines Revenue million Forecast, by Application 2020 & 2033
Table 10: Global Adult Preventable Vaccines Volume K Forecast, by Application 2020 & 2033
Table 11: Global Adult Preventable Vaccines Revenue million Forecast, by Country 2020 & 2033
Table 12: Global Adult Preventable Vaccines Volume K Forecast, by Country 2020 & 2033
Table 13: United States Adult Preventable Vaccines Revenue (million) Forecast, by Application 2020 & 2033
Table 14: United States Adult Preventable Vaccines Volume (K) Forecast, by Application 2020 & 2033
Table 91: Rest of Asia Pacific Adult Preventable Vaccines Revenue (million) Forecast, by Application 2020 & 2033
Table 92: Rest of Asia Pacific Adult Preventable Vaccines Volume (K) Forecast, by Application 2020 & 2033
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
Web Analytics
Survey Reports
Research Institute
Latest Research Reports
Opinion Leaders
Secondary Research
Annual Reports
White Paper
Latest Press Release
Industry Association
Paid Database
Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Adult Preventable Vaccines?
The projected CAGR is approximately XX%.
2. Which companies are prominent players in the Adult Preventable Vaccines?
Key companies in the market include Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc (GSK), Sanofi Pasteur, Moderna, Inc., Serum Institute of India Pvt., Bharat Biotech International, CSL Limited (Seqirus), Emergent BioSolutions Inc., Daiichi Sankyo Company, Novavax, Inc., Sinovac Biotech, Sinopharm Group Co.,, Johnson & Johnson (Janssen), AstraZeneca plc.
3. What are the main segments of the Adult Preventable Vaccines?
The market segments include Type, Application.
4. Can you provide details about the market size?
The market size is estimated to be USD 29810 million as of 2022.
5. What are some drivers contributing to market growth?
N/A
6. What are the notable trends driving market growth?
N/A
7. Are there any restraints impacting market growth?
N/A
8. Can you provide examples of recent developments in the market?
N/A
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4480.00, USD 6720.00, and USD 8960.00 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in million and volume, measured in K.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Adult Preventable Vaccines," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Adult Preventable Vaccines report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Adult Preventable Vaccines?
To stay informed about further developments, trends, and reports in the Adult Preventable Vaccines, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Adult Preventable Vaccines